Last reviewed · How we verify
Lanreotide Autogel and Octreotide LAR — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Lanreotide Autogel and Octreotide LAR (Lanreotide Autogel and Octreotide LAR) — Odense University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lanreotide Autogel and Octreotide LAR TARGET | Lanreotide Autogel and Octreotide LAR | Odense University Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lanreotide Autogel and Octreotide LAR CI watch — RSS
- Lanreotide Autogel and Octreotide LAR CI watch — Atom
- Lanreotide Autogel and Octreotide LAR CI watch — JSON
- Lanreotide Autogel and Octreotide LAR alone — RSS
Cite this brief
Drug Landscape (2026). Lanreotide Autogel and Octreotide LAR — Competitive Intelligence Brief. https://druglandscape.com/ci/lanreotide-autogel-and-octreotide-lar. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab